Fig. 8: DHX9 inhibitors increase the chemosensitivity of SCLC. | Oncogene

Fig. 8: DHX9 inhibitors increase the chemosensitivity of SCLC.

From: KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway

Fig. 8: DHX9 inhibitors increase the chemosensitivity of SCLC.The alternative text for this image may have been generated using AI.

A Inhibitory effects of different concentrations of DHX9-IN-2 combined with cisplatin and etoposide on H69AR cells. B The results of the CCK8 assay showing the IC50 of cisplatin and etoposide in H69AR cells when they are combined with 3 μM DHX9-IN-2. IC50, the half-maximal inhibitory concentration. C Growth curves of tumors derived from H69AR cells and treated with chemotherapy and/or DHX9 inhibitors (n = 5). D Images of subcutaneous tumors derived from H69AR cells after chemotherapy with or without DHX9 inhibitors are shown. E Comparison of tumor weight between the groups treated with chemotherapy with or without DHX9 inhibitors. F, G Bioluminescence imaging signals from mice with orthotopic SCLC tumors were measured on Days 7, 14, 21, and 28 (n = 6). The top panel of F shows the scheme of the therapeutic strategy for the SCLC orthotopic tumor. H Weight curve of the mice. HSA, The Highest Single Agent model; DDP, Cisplatin; VP-16, Etoposide; ***, p < 0. 001; **, p < 0. 01; *, p < 0.05; ns, not significant.

Back to article page